

# Sandhya Vasan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5448309/publications.pdf>

Version: 2024-02-01

47  
papers

1,285  
citations

430874

18  
h-index

395702

33  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2243  
citing authors

#	ARTICLE	IF	CITATIONS
1	A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23652-23662.	7.1	193
2	In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS ONE, 2011, 6, e19252.	2.5	160
3	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV, the, 2019, 6, e297-e306.	4.7	73
4	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Science Translational Medicine, 2022, 14, .	12.4	73
5	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. Journal of Infectious Diseases, 2017, 215, 1255-1263.	4.0	57
6	Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine. PLoS ONE, 2010, 5, e8816.	2.5	47
7	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. Npj Vaccines, 2021, 6, 129.	6.0	47
8	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	44
9	Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine. PLoS ONE, 2010, 5, e8617.	2.5	41
10	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathogens, 2017, 13, e1006182.	4.7	38
11	A DNA-Based Candidate HIV Vaccine Delivered via <i>In Vivo</i> Electroporation Induces CD4 Responses toward the $\pm 41^27$ -Binding V2 Loop of HIV gp120 in Healthy Volunteers. Vaccine Journal, 2012, 19, 1557-1559.	3.1	36
12	Current approaches to HIV vaccine development: a narrative review. Journal of the International AIDS Society, 2021, 24, e25793.	3.0	35
13	Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. Journal of Virology, 2018, 92, .	3.4	33
14	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV, the, 2020, 7, e238-e248.	4.7	33
15	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. PLoS Pathogens, 2021, 17, e1009339.	4.7	32
16	Transgender populations and HIV: unique risks, challenges and opportunities. Journal of Virus Eradication, 2016, 2, 87-93.	0.5	29
17	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. Journal of Clinical Investigation, 2020, 130, 3299-3304.	8.2	24
18	$CD^+$ Cell infiltration into subcutaneous adipose tissue is not indicative of productively infected cells during acute SHIV infection. Journal of Medical Primatology, 2017, 46, 154-157.	0.6	22

#	ARTICLE	IF	CITATIONS
19	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	3.4	19
20	Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?. <i>Frontiers in Immunology</i> , 2021, 12, 710044.	4.8	18
21	HIV vaccine delayed boosting increases Env variable region 2â€™specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	5.0	18
22	Transgender populations and HIV: unique risks, challenges and opportunities. <i>Journal of Virus Eradication</i> , 2016, 2, 87-93.	0.5	17
23	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. <i>PLoS ONE</i> , 2018, 13, e0196397.	2.5	14
24	Cognitive trajectories after treatment in acute HIV infection. <i>Aids</i> , 2021, 35, 883-888.	2.2	13
25	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	4.7	13
26	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. <i>PLoS Pathogens</i> , 2021, 17, e1009785.	4.7	12
27	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020, 5, .	5.0	12
28	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , 2020, 5, .	5.0	12
29	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A33-A33.	1.1	11
30	Neurocognitive impact of Zika virus infection in adult rhesus macaques. <i>Journal of Neuroinflammation</i> , 2022, 19, 40.	7.2	11
31	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	9
32	Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1010105.	4.7	9
33	DNA Vaccination by Electroporation Amplifies Broadly Cross-Restricted Public TCR Clonotypes Shared with HIV Controllers. <i>Journal of Immunology</i> , 2017, 199, 3437-3452.	0.8	7
34	HIV Vaccine Efficacy Trials: RV144 and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 3-30.	1.6	6
35	Impact of analytical treatment interruption on the central nervous system in a simian-HIV model. <i>Aids</i> , 2019, 33, S189-S196.	2.2	6
36	HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development. <i>Current HIV/AIDS Reports</i> , 2022, 19, 86.	3.1	6

#	ARTICLE	IF	CITATIONS
37	HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLoS Pathogens, 2022, 18, e1010369.	4.7	5
38	Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection. Clinical Infectious Diseases, 0, , .	5.8	5
39	RV306, an Evaluation of a 48 Week ALVAC-HIV AIDSVAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections. AIDS Research and Human Retroviruses, 2014, 30, A264-A264.	1.1	4
40	Factors influencing estimates of HIV-1 infection timing using BEAST. PLoS Computational Biology, 2021, 17, e1008537.	3.2	4
41	Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. EclinicalMedicine, 2021, 38, 101033.	7.1	4
42	Vaccine development lessons between HIV and COVID-19. Lancet Infectious Diseases, The, 2021, 21, 759-761.	9.1	3
43	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. Virus Evolution, 2021, 7, veab057.	4.9	2
44	Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth. Journal of Virology, 2021, 95, e0079721.	3.4	2
45	Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand. AIDS Research and Therapy, 2022, 19, .	1.7	2
46	Vaccine Induced Seroreactivity in RV144 Vaccine Recipients in RV305, a Placebo Controlled Assessment of Late Boosts with ALVAC-HIV and AIDSVAX B/E. AIDS Research and Human Retroviruses, 2014, 30, A191-A191.	1.1	0
47	Unique HIV Risk Factors and Prevention Needs for Transgender Women and Cisgender Men Who Have Sex with Men in Bangkok, Thailand. Transgender Health, 0, , .	2.5	0